Viatris agrees to buy Pacira BioSciences for $36.50 a share in cash, $1.65 billion
Viatris signed a merger agreement on October 8, 2026 to acquire Pacira BioSciences through a cash tender offer at $36.50 per share, an aggregate equity value of $1.65 billion. Viatris said it expects to fund the deal primarily from excess cash, with the rest from short-term borrowings, and expects it to be immediately accretive to its financial guidance metrics and to close by the end of 2026. The deal is a large acquisition that would add Pacira's marketed EXPAREL and ZILRETTA products to Viatris.
Key points
- Offer price of $36.50 per share in cash; aggregate equity value of $1.65 billion per the joint press release.
- Pacira generated approximately $746 million in total revenue and $177 million in adjusted EBITDA for the twelve months ended June 30, 2026.
- Completion requires a majority of Pacira shares tendered; the offer is open for 10 business days, and the merger agreement's outside date is April 8, 2027.
- Pacira would pay Viatris a $62 million termination fee under specified circumstances, including a Superior Offer.
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.